{
    "Trade/Device Name(s)": [
        "RapidSense Drugs of Abuse Cocaine (COC) 300 Device"
    ],
    "Submitter Information": "QuantRx Biomedical Corporation",
    "510(k) Number": "K080436",
    "Predicate Device Reference 510(k) Number(s)": [
        "K010841"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "DIO"
    ],
    "Summary Letter Date": "February 6, 2009",
    "Summary Letter Received Date": "February 9, 2009",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21CFR862.3250"
    ],
    "Regulation Name(s)": [
        "Cocaine and cocaine metabolite test system"
    ],
    "Analyte Class(es)": [
        "toxicology"
    ],
    "Analyte(s)": [
        "Benzoylecgonine"
    ],
    "Specimen Type(s)": [
        "Urine"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [],
    "Method(s)/Technology(ies)": [
        "Lateral flow competitive immunoassay"
    ],
    "Methodologies": [
        "Immunoassay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Test"
    ],
    "Document Summary": "FDA 510(k) summary for RapidSense Drugs of Abuse Cocaine (COC) 300 Device, a lateral flow immunoassay for qualitative detection of benzoylecgonine in urine at 300 ng/mL cutoff",
    "Indications for Use Summary": "Qualitative detection of cocaine metabolite benzoylecgonine in human urine at 300 ng/mL cutoff for professional laboratory use; preliminary screening only, with GC/MS confirmatory testing recommended",
    "fda_folder": "Toxicology"
}